These approvals were based on robust data which showed Trelegy Ellipta improved lung function and symptom control in adult asthma patients.” GSK reveals the survival data that it reckons could ...

Trelegy Ellipta got its first US approval in September ... Trelegy was approved in Europe last week in COPD maintenance therapy. But GSK is already seeking an expanded US label for maintenance ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler that’s prescribed for COPD. This article covers topics such as side effects, dosage ...

Are you a print subscriber? Activate your account. By Ad Age Studio 30 - 3 min 2 sec ago By Ewan Larkin - 39 min 35 sec ago By Matt McCain - 3 hours 9 min ago By Lenore Moritz - 3 hours 34 min ago ...

GSK plc GSK reported adjusted earnings of 72 ... Anoro Ellipta, Breo Ellipta and Trelegy Ellipta and the continued post-pandemic recovery of the antibiotic market outside the United States.

GSK plc GSK reported third-quarter 2024 core ... the upside was primarily driven by solid sales growth of asthma inhaler ...

GSK reported core earnings of $1.27 per American ... This upside was driven by solid sales growth of the asthma inhaler Trelegy Ellipta across all regions, reflecting patient demand.

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter ... The company added General Medicines, including Trelegy, also continued to perform better than expected. Trelegy (asthma drug) sales reached ...